Ontology highlight
ABSTRACT:
SUBMITTER: Annunziata M
PROVIDER: S-EPMC7280484 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Annunziata Mario M Bonifacio Massimiliano M Breccia Massimo M Castagnetti Fausto F Gozzini Antonella A Iurlo Alessandra A Pregno Patrizia P Stagno Fabio F Specchia Giorgina G
Frontiers in oncology 20200602
The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), thr ...[more]